Oasmia Pharmaceutical AB - Oasmia extends its production agreement with Baxter

Oasmia Pharmaceutical AB - Oasmia extends its production agreement with Baxter

Oasmia Pharmaceutical AB

UPPSALA, Sweden, June 24, 2014 - The Swedish pharmaceutical company Oasmia Pharmaceutical AB (publ) today announced that it has extended its production collaboration with Baxter's BioPharma Solutions around Oasmia's products. Uppsala, Sweden, 2014-06-24 08:59 CEST (GLOBE NEWSWIRE) -- Oasmia and Baxter's BioPharma Solutions, which is the contract manufacturing arm of Baxter International Inc., has signed a Master Manufacturing Agreement to cover future Oasmia products today in clinical or development phase. This agreement is a compliment to the already existing Contract Manufacturing Agreement for Oasmia's two oncology products Paclical and Paccal Vet(R)-CA1.

"The extended agreement will secure large-scale manufacturing to meet future market demands of Oasmia's products. It will provide a good supply of high quality products to our customers", commented Julian Aleksov, CEO and President of Oasmia.

Doxophos, which is developed for the treatment of several cancer types in humans, including breast cancer, and Doxophos Vet, which is for the treatment of lymphoma in companion animals, are the next product candidates entering scale up by Baxter.

Oasmia and Baxter have recently successfully transferred and validated large scale production of Paclical and Paccal Vet-CA1at the Baxter Halle facility and is expected to be approved by the authorities well in time for expected increased market demands of Oasmia's products. The extension of the agreement means that Oasmia can source products both from its own Uppsala plant and Baxter's plant. Notes to editors:

About Oasmia Pharmaceutical

AB Oasmia Pharmaceutical AB develops new generations of drugs in the field of human and veterinary oncology. The company's product development aims to create and manufacture novel nanoparticle formulations and drug-delivery systems based on well-established cytostatics, which, in comparison with current alternatives, show improved properties, reduced side effects, and expanded applications. The company's product development is based on its proprietary in-house research and company patents. Oasmia is listed on NASDAQ OMX Stockholm (OASM) and the Frankfurt Stock Exchange (OMAX, ISIN SE0000722365). www.oasmia.com Mikael Widell, Vice President Communications Mobile: +46 70 311 99 60 E-mail: [email protected] https://newsclient.omxgroup.com/cdsPublic/viewDisclosure.action?disclosureId=614925&messageId=762312 https://newsclient.omxgroup.com/cds/DisclosureAttachmentServlet?messageAttachmentId=478767